Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-23 in first-line high-risk large B-cell lymphoma
jRCT2023240034Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Axicabtagene ciloleucel with Standard of care therapy (2 arms). Primary endpoint: Event-free survival. Started Jan 2025; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2023240034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2023240034.